Mark Kristoffer U. Pasayan
A5013427731- HIV/AIDS Research and Interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- Tuberculosis Research and Epidemiology
- HIV Research and Treatment
- Pregnancy and Medication Impact
- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Adolescent Sexual and Reproductive Health
- HIV-related health complications and treatments
Research Institute for Tropical Medicine
2017-2024
Abstract Background While people with human immunodeficiency virus (PWH) start antiretroviral treatment (ART) regardless of CD4 count, measurement remains crucial for detecting advanced (HIV) disease and evaluating ART programs. We explored (proportion PWH a result available) prevalence <200 cells/µL (hereafter “CD4 <200”) at initiation within the International epidemiology Databases to Evaluate AIDS (IeDEA) global collaboration. Methods included participating programs who...
Background: The transition to dolutegravir-containing antiretroviral therapy (ART) in low- and middle-income countries (LMICs) was complicated by an initial safety signal May 2018 suggesting that exposure dolutegravir at conception possibly associated with infant neural tube defects. On the basis of additional evidence, July 2019, World Health Organization recommended for all adults adolescents living HIV. Objective: To describe uptake disparities sex age group LMICs. Design: Observational...
Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other serious bacterial infections in HIV-infected patients. Despite its vitro activity Mycobacterium tuberculosis, the effects of CTX preventive therapy on tuberculosis (TB) remain unclear. Adults living with HIV enrolled a regional observational cohort Asia who had initiated combination antiretroviral (cART) were included analysis. Factors associated new TB diagnoses after entry survival...
Abstract Objective To describe changes in atherosclerotic cardiovascular disease (ASCVD) risk over time among people living with HIV (PLHIV). Methods We used data from the TREAT Asia Observational Database (TAHOD) and Australian (AHOD). Five-year ASCVD was calculated using D:A:D equation. Individuals were eligible for inclusion if they aged ≥18 years, had started ART, no previous history of complete factor available within first 5 years ART initiation. Results A total 3368 adults contributed...
Background: While recognized as a key HIV prevention strategy, preexposure prophylaxis (PrEP) availability and accessibility are not well documented globally. We aimed to describe PrEP drug registration status the of services across care sites participating in International epidemiology Databases Evaluate AIDS (IeDEA) research consortium. Methods: used country-level from Vaccine Advocacy Coalition data IeDEA surveys conducted 2014, 2017 2020 among clinics seven global regions. descriptive...
Abstract Background Mycobacterium avium–intracelllulare complex (MAC) prophylaxis is recommended for patients with CD4 counts of < 50 cells/mm3. With the significant decrease in incidence disseminated MAC infection and effective immune recovery due to availability combination antiretroviral therapy (ART), benefits giving were investigated. This study examined impact macrolide on AIDS-defining conditions HIV-associated mortality a cohort HIV-infected ART. Methods TREAT Asia HIV...
Mycobacterium avium complex prophylaxis is recommended for patients with advanced HIV infection. With the decrease in incidence of disseminated infection and availability antiretroviral therapy (ART), benefits macrolide were investigated. This study examined impact on AIDS-defining conditions HIV-associated mortality a cohort HIV-infected ART.Patients from TREAT Asia Observational Database (September 2015 data transfer) aged 18 years older CD4 count <50 cells/mm at ART initiation included....